Amgen Inc. has announced the initiation of a Phase 3 clinical program for maridebart cafraglutide (MariTide), an investigational therapy aimed at treating obesity and related conditions. This development follows positive results from a Phase 2 study, which demonstrated promising outcomes in weight loss. MariTide employs a unique mechanism by blocking the GIPR pathway and activating the GLP-1 receptor, a strategy grounded in both preclinical and human genetic research. The company continues to explore the biological pathways involved in obesity through its subsidiary, deCODE genetics, to refine and enhance therapeutic approaches. Further details on the Phase 3 program are anticipated in future communications from Amgen.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amgen Inc. published the original content used to generate this news brief on September 03, 2025, and is solely responsible for the information contained therein.